[{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Amiselimod HCl","moa":"S1P receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Karolinska Institute"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"QBECO-SSI","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : MT-1303 (amiselimod HCl) is a sphingosine-1-phosphate receptor functional antagonist, which is being evaluated in Phase II clinical trial studies with patients for the treatment of ulcerative colitis.

                          Product Name : MT-1303

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 21, 2023

                          Lead Product(s) : Amiselimod HCl

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : QBECO-SSI treatment, which is designed to restore normal innate immune function, immune homeostasis, and barrier function in the GI tract, provides a novel potentially transformative alternative to immunosuppressive therapies for patients living with IBD...

                          Product Name : QBECO-SSI

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 14, 2022

                          Lead Product(s) : QBECO-SSI

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Karolinska Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : This new equity funding that will allow team and play an essential role in initiating three new Phase 2 randomized placebo-controlled clinical studies of Qbeco. Two of these important trials are in critical indications for which there are no effective tr...

                          Product Name : QBECO-SSI

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          March 21, 2022

                          Lead Product(s) : QBECO-SSI

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          blank